AN2 Therapeutics (ANTX) Long-Term Investments (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Long-Term Investments for 5 consecutive years, with $2.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Long-Term Investments fell 59.91% year-over-year to $2.0 million; the TTM figure through Dec 2025 stood at $2.0 million (down 59.91% YoY), while the FY2025 annual figure was $2.0 million, down 59.91% from the prior year.
• Long-Term Investments slipped to $2.0 million in Q4 2025 per ANTX's latest filing, from $3.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $27.2 million in Q4 2023 and bottomed at $2.0 million in Q3 2022.
• Historically, Long-Term Investments has averaged $8.2 million across 5 years, with a median of $3.7 million in 2021.
• Annual changes were most pronounced in 2023 — Long-Term Investments jumped 1223.09% — and 2024, when it tumbled 81.54%.
• AN2 Therapeutics' Long-Term Investments stood at $3.5 million in 2021, then dropped by 7.66% to $3.2 million in 2022, then jumped by 744.8% to $27.2 million in 2023, then sank by 81.54% to $5.0 million in 2024, then sank by 59.91% to $2.0 million in 2025.
• Business Quant data shows ANTX's Long-Term Investments at $2.0 million in Q4 2025, $3.2 million in Q3 2025, and $8.3 million in Q2 2025.